Can-Fite Biopharma Has Completed The Design Of Phase 2A Study Protocol For Pancreatic Cancer And Plans To Submit The Protocol Shortly To Ethical Committees For Approval, Study Will Aim To Enroll About 20 Patients To Establish Safety And Clinical Activity
Can-Fite Biopharma Has Completed The Design Of Phase 2A Study Protocol For Pancreatic Cancer And Plans To Submit The Protocol Shortly To Ethical Committees For Approval, Study Will Aim To Enroll About 20 Patients To Establish Safety And Clinical Activity
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.